‘When it comes to developing medicines available for all populations in the world, the image of Big Pharma has long been tarnished. Supply bottlenecks for some specific drugs are often the result of the pricing policies pursued by major drugmakers, says Wasem [Jürgen Wasem, a professor for healthcare management at the University of Duisburg-Essen in Germany] — a claim, which is nonetheless "difficult to prove in most cases," he says. Sometimes, companies strive to keep supply artificially low, he says, to achieve higher market prices. Moreover, certain treatments are often never developed because there isn't a "commercial incentive" to undertake the effort, he adds.’
Read here (DW, May 1, 2020)
Worst ever Covid variant? Omicron
John Campbell shares his findings on Omicron. View here (Youtube, Nov 27, 2021)
-
On September 14th 2020, the GPMB released its second report titled, A World in Disorder. In this report, the GPMB provides a harsh assessmen...
-
‘A focus on the coronavirus has disrupted detection and treatment of other infectious diseases. Governments and funders can do four things t...
-
‘We also used this investigation to quantify the impact of behaviours (i.e. mask wearing, handwashing) that were promoted to reduce the risk...